Trial Search Results

Dose-Response Study of Sodium Nitroprusside in Children Requiring Controlled Hypotension in the Operating Room

Sodium nitroprusside (SNP) has been approved for control of blood pressure in adults, yet there are no controlled studies in children. The purpose of this study is to determine the efficacy and safety of sodium nitroprusside in children who will be having surgery, and who require blood pressure lowering in order to decrease the amount of blood loss during their surgery.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Collaborator: Duke University

Stanford Investigator(s):

Intervention(s):

  • Drug: nitroprusside

Phase:

Phase 2

Eligibility


Inclusion Criteria:

Study subjects must meet all of the following criteria:

   - Subject is less than 17 years of age

   - Neonates must be full-term gestation and have a body weight of at least 2.5 kg

   - Subject requires pharmacologically-induced hypotension for acute blood pressure
   management for surgery or other invasive procedure, e.g., cerebral artery embolization

   - Duration of the subject's controlled hypotension is expected to be ≥ 2 hours

   - Subject requires general anesthesia with endotracheal intubation

   - Subject requires placement of intra-arterial line during the surgical or medical
   procedure

   - The subject's parent or legal guardian gives permission (informed consent) and subject
   gives assent when appropriate.

Exclusion Criteria:

Subjects will be excluded if any of the following criteria exist:

   - Subject has a known allergy to SNP

   - Subject has a known mitochondrial cytopathy with a disorder of oxidative
   phosphorylation or of respiratory chain enzymes

   - Subject has a contraindication to vasodilator therapy for control of blood pressure
   during surgery or procedures

   - Subject has participated in other clinical trials for investigational drugs and/or
   devices within 30 days prior to enrollment

   - Subject has any serious medical condition which, in the opinion of the investigator,
   is likely to interfere with study procedures

   - Subject is moribund (death likely to occur within 48 hours)

   - Subject has a positive result for the urine or serum human chorionic gonadotropin
   (HCG) test administered at screening.

Ages Eligible for Study

N/A - 17 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting